Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. reports developments as a clinical-stage life sciences company focused on rebalancing inflammation with its proprietary formulation Gemini. Company updates center on Gemini programs for acute kidney injury, chronic kidney disease, prevention of post-surgical infection, and severe burn-related hyperinflammation and infection.
Recurring announcements include clinical data from the PRIME study, FDA interactions tied to the AKI development pathway, advisory and conference activity, quarterly financial results, warrant inducement financings, proxy matters, and capital-structure actions such as reverse stock splits and Nasdaq listing compliance matters.
Revelation Biosciences, Inc. (NASDAQ: REVB) announced its financial results for the three months ended March 31, 2024. The company reported $14.6 million in cash and cash equivalents, up from $12.0 million in December 2023. They stated that the current cash is enough to fund operations through 2024. However, they reported a net loss of $2.7 million for the quarter, with significant expenses related to GEM-AKI and GEM-SSI clinical studies impacting their financials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.